

Renaud Felten

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4765942/renaud-felten-publications-by-citations.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

44
papers

611
citations

13
h-index

23
g-index

63
ext. papers

1,085
ext. citations

6.2
avg, IF

4.51
L-index

#	Paper	IF	Citations
44	The world-wide burden of musculoskeletal diseases: a systematic analysis of the World Health Organization Burden of Diseases Database. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 844-848	2.4	83
43	COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. <i>Lancet Rheumatology, The</i> , 2021 , 3, e419-e426	14.2	81
42	The 2018 pipeline of targeted therapies under clinical development for Systemic Lupus Erythematosus: a systematic review of trials. <i>Autoimmunity Reviews</i> , 2018 , 17, 781-790	13.6	47
41	Vaccination against COVID-19: Expectations and concerns of patients with autoimmune and rheumatic diseases. <i>Lancet Rheumatology, The</i> , 2021 , 3, e243-e245	14.2	43
40	Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014. <i>Autoimmunity Reviews</i> , 2020 , 19, 102531	13.6	36
39	10 most important contemporary challenges in the management of SLE. <i>Lupus Science and Medicine</i> , 2019 , 6, e000303	4.6	33
38	Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date. <i>Drug Design, Development and Therapy</i> , 2019 , 13, 1535-1543	4.4	32
37	Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	24
36	Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study. <i>Lancet Rheumatology, The</i> , 2021 , 3, e613-e615	14.2	23
35	The pipeline of targeted therapies under clinical development for primary Sjögren's syndrome: A systematic review of trials. <i>Autoimmunity Reviews</i> , 2019 , 18, 576-582	13.6	20
34	Defective BTLA functionality is rescued by restoring lipid metabolism in lupus CD4+ T cells. <i>JCI Insight</i> , 2018 , 3,	9.9	20
33	Advances in the treatment of systemic lupus erythematosus: From back to the future, to the future and beyond. <i>Joint Bone Spine</i> , 2019 , 86, 429-436	2.9	15
32	At the crossroads of gout and psoriatic arthritis: "psout". <i>Clinical Rheumatology</i> , 2020 , 39, 1405-1413	3.9	14
31	Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab. <i>Lancet Rheumatology, The</i> , 2021 ,	14.2	13
30	Refining "Long-COVID" by a Prospective Multimodal Evaluation of Patients with Long-Term Symptoms Attributed to SARS-CoV-2 Infection. <i>Infectious Diseases and Therapy</i> , 2021 , 10, 1747-1763	6.2	12
29	Do JAK inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIK-SFR Registry. <i>Lancet Rheumatology, The</i> , 2021 ,	14.2	11
28	Osteonecrosis of the femoral head linked to topical steroids for skin bleaching: a case report. <i>Annals of Internal Medicine</i> , 2014 , 161, 763-4	8	10

27	Characterization of auto-immune hepatitis associated with the use of anti-TNF α agents: An analysis of 389 cases in VigiBase. <i>Autoimmunity Reviews</i> , 2020 , 19, 102460	13.6	9
26	Cluster analysis reveals three main patterns of beliefs and intention with respect to SARS-CoV-2 vaccination in patients with autoimmune and inflammatory diseases. <i>Rheumatology</i> , 2021 , 60, S168-S176	3.9	9
25	Avascular osteonecrosis in kidney transplant recipients: Risk factors in a recent cohort study and evaluation of the role of secondary hyperparathyroidism. <i>PLoS ONE</i> , 2019 , 14, e0212931	3.7	7
24	B-cell targeted therapy is associated with severe COVID-19 among patients with inflammatory arthritides: a 1-year multicentre study in 1116 successive patients receiving intravenous biologics. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	7
23	Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure. <i>Lancet Rheumatology, The</i> , 2021 , 3, e553-e562	14.2	6
22	Response to: 'Correspondence on 'Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial'' by Wang. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	5
21	Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge.. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022 , 14, 1759720X211073001	3.8	5
20	Immunosuppressive agents for rheumatoid arthritis: a systematic review of clinical trials and their current development stage. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020 , 12, 1759720X20959971	3.8	4
19	The history of lupus throughout the ages. <i>Journal of the American Academy of Dermatology</i> , 2020 ,	4.5	4
18	Refining myositis associated with primary Sjögren's syndrome: data from the prospective cohort ASSESS. <i>Rheumatology</i> , 2021 , 60, 675-681	3.9	4
17	Effect of SARS-CoV-2 Vaccination on Symptoms from Post-Acute Sequelae of COVID-19: Results from the Nationwide VAXILONG Study.. <i>Vaccines</i> , 2021 , 10,	5.3	4
16	Shared development of targeted therapies among autoimmune and inflammatory diseases: a systematic repurposing analysis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020 , 12, 1759720X20969261	3.8	3
15	Acceptability of the COVID-19 vaccine among patients with chronic rheumatic diseases and health-care professionals: a cross-sectional study in 19 Arab countries.. <i>Lancet Rheumatology, The</i> , 2021 ,	14.2	3
14	Response to: 'Correspondence on 'Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial'' by de Wolff. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	2
13	Prescription strategy of antimalarials in cutaneous and systemic lupus erythematosus: an international survey. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021 , 13, 1759720X211002595	3.8	2
12	Psoriatic arthritis with hyperuricemia: more peripheral, destructive, and challenging to treat.. <i>Clinical Rheumatology</i> , 2022 , 1	3.9	1
11	High BTLA Expression Likely Contributes to Contraction of the Regulatory T Cell Subset in Lupus Disease.. <i>Frontiers in Immunology</i> , 2021 , 12, 767099	8.4	1
10	Advances in treatments for Sjögren's syndrome: the glass is half full. <i>Lancet Rheumatology, The</i> , 2020 , 2, e516-e518	14.2	1

9	Rheumatic presentations of Guillain-Barré syndrome as a diagnostic challenge: A case series. <i>Joint Bone Spine</i> , 2021 , 88, 105144	2.9	1
8	Acute renal failure in systemic sclerosis revealing Goodpasture syndrome: "All that glitters is not scleroderma renal crisis".. <i>Journal of Scleroderma and Related Disorders</i> , 2020 , 5, NP1-NP5	2.3	1
7	Fibrous nodules over the patella revealing acrodermatitis chronica atrophicans. <i>Joint Bone Spine</i> , 2015 , 82, 208	2.9	0
6	Different anti-SARS-CoV-2 vaccine response under B- and T-cell targeted therapies versus anti-cytokine therapies in patients with inflammatory arthritides.. <i>Joint Bone Spine</i> , 2022 , 89, 105391	2.9	0
5	Les traitements du lupus systémique : retour vers le futur. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2019 , 86, 573-581	0.1	
4	Comment on: Refining myositis associated with primary Sjögren's syndrome: data from the prospective cohort ASSESS: Reply. <i>Rheumatology</i> , 2021 ,	3.9	
3	Outcome Measures in Sjögren Syndrome and Perspectives in Clinical Trial Design 2016 , 263-271		
2	Responding to and Driving Change in Rheumatology: Report from the 12th International Immunology Summit 2021.. <i>Rheumatology and Therapy</i> , 2022 , 9, 705	4.4	
1	Is there still a place for methotrexate in severe psoriatic arthritis?. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022 , 14, 1759720X221092376	3.8	